A Java Reference Model of Transacted Memory for Smart Cards

Transacted Memory offers persistence, undoability and auditing. We present a Java/JML Reference Model of the Transacted Memory system on the basis of our earlier separate Z model and C implementation. We conclude that Java/JML combines the advantages of a high level specification in the JML part (based on our Z model), with a detailed implementation in the Java part (based on our C implementation)

Java Card:An analysis of the most successful smart card operating system

To explain why the Java Card operating system has become the most successful smart card operating system to date, we analyze the realized features of the current Java Card version, we argue it could be enhanced by adding a number of intended features and we discuss a set of complementary features that have been suggested. No technology can be successful without the right people and the right circumstances, so we provide some insights in the personal and historical historic aspects of the success of Java Card

Targeting tumor stromal cells through a PDGF-beta receptor binding carrier

Tumor stromal cells significantly contribute to tumor growth and abundantly express platelet-derived growth factor-beta receptor (PDGF-βR). In this study, we targeted stromal as well as tumor cells using our PDGF-βR binding carrier (pPB-HSA). pPB-HSA showed PDGF-βR-specific binding in-vitro and, in-vivo it rapidly accumulated in C26 tumors in mice after i.v. injection. We conjugated doxorubicin to pPB-HSA and, the conjugate showed antitumor effects in-vitro in tumor and stromal cells and in-vivo in C26-tumor bearing mice

SCENIHR (Scientific Committee on Emerging and Newly Identified Health Risks) Opinion on The safety of the use of bisphenol A in medical devices

SCENIHR (Scientific Committee on Emerging and Newly Identified Health Risks), Safety of the use of bisphenol A in medical devices, 18 February 2015Testai, Emanuela; Hartemann, Philippe; Rodríguez-Farré, Eduard; Rastogi, Suresh Chandra; de Jong, Wim; Bustos, Juana; Castle, Laurence; Gundert-Remy, Ursula; Hensten, Arne; Kopperud, Hilde Molvig; Olea, Nicolás; Piersma, Aldert; SCENIHR (Scientific Committee on Emerging and Newly Identified Health Risks). The Safety of the use of Bisphenol A in medical devices. [S.l.]: European Commission, 2015. 166 p. ISSN 1831-4783 . ISBN 978-92-79-30133-9 . DOI Doi: 10.2772/75546This opinion assesses whether the use of bisphenol A in medical devices such as implants, catheters, and dental devices could give reasons for safety concerns, to provide indications on limit values for BPA release from medical devices and to identify any patient group, e.g. infants, pregnant and breastfeeding women who would be particularly at risk. Several exposure scenarios have been evaluated taking into account the material used, information related to BPA leaching, the duration of a single treatment and the frequency of treatments, giving rise to toxicologically relevant acute, short and long term exposure. The SCENIHR concludes that risk for adverse effects of BPA may exist when the BPA is directly available for systemic exposure after non-oral exposure routes, especially for neonates in intensive care units, infants undergoing prolonged medical procedures and for dialysis patients. Although the benefit of medical devices has also to be considered, the SCENIHR recommends that, where practicable, medical devices that do not leach BPA should be used. The possibility of replacing BPA in these products should be considered against their efficiency in the treatment, as well as the toxicological profile of the alternative materials. However, better data on exposure would be beneficial for the refinement of the present risk assessment, to be carried out when new data on exposure via medical devices will be available.Peer Reviewe